Pharmacokinetics and immunogenicity of a recombinant human butyrylcholinesterase bioscavenger in macaques following intravenous and pulmonary delivery

被引:12
|
作者
Rosenberg, Yvonne J. [1 ]
Adams, Robert J. [2 ]
Hernandez-Abanto, Segundo [1 ]
Jiang, Xiaoming [1 ]
Sun, Wei [3 ]
Mao, Lingjun [1 ]
Lee, K. David [1 ]
机构
[1] PlantVax Inc, Rockville, MD 20850 USA
[2] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA
[3] Walter Reed Army Inst Res, Div Biochem, Silver Spring, MD 20910 USA
基金
美国国家卫生研究院;
关键词
Human butyrylcholinesterase; Pharmacokinetics; Immunogenicity; Aerosol delivery; Monkey model; Animal Rule; HUMAN SERUM BUTYRYLCHOLINESTERASE; N-GLYCOLYLNEURAMINIC ACID; PROTECTION; TOXICITY; ACETYLCHOLINESTERASE; MODEL; SOMAN; PRETREATMENT; STABILITY; PRODUCTS;
D O I
10.1016/j.cbi.2015.09.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant (r) and native butyrylcholinesterse (BChE) are potent bioscavengers of organophosphates (OPs) such as nerve agents and pesticides and are undergoing development as antidotal treatments for OP-induced toxicity. Because of the lethal properties of such agents, regulatory approval will require extensive testing under the Animal Rule. However, human (Hu) glycoprotein biologicals, such as BChE, present a challenge for assessing immunogenicity and efficacy in heterologous animal models since any immune responses to the small species differences in amino acids or glycans between the host and biologic may alter pharmacodynamics and preclude accurate efficacy testing; possibly underestimating their potential protective value in humans. To establish accurate pharmacokinetic and efficacy data, an homologous animal model has been developed in which native and PEGylated forms of CHO-derived rMaBChE were multiply injected into homologous macaques with no induction of antibody. These now serve as controls for assessing the pharmacokinetics and immunogenicity in macaques of multiple administrations of PEGylated and unmodified human rBChE (rHuBChE) by both intravenous (IV) and pulmonary routes. The results indicate that, except for maximal concentration (Cmax), the pharmacokinetic parameters following IV injection with heterologous PEG-rHuBChE were greatly reduced even after the first injection compared with homologous PEG-rMaBChE. Anti-HuBChE antibody responses were induced in all monkeys after the second and third administrations regardless of the route of delivery; impacting rates of clearance and usually resulting in reduced endogenous MaBChE activity. These data highlight the difficulties inherent in assessing pharmacokinetics and immunogenicity in animal models, but bode well for the efficacy and safety of rHuBChE pretreatments in homologous humans. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 50 条
  • [1] Pulmonary delivery of an aerosolized recombinant human butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques
    Rosenberg, Yvonne J.
    Laube, Beth
    Mao, Lingjun
    Jiang, Xiaoming
    Hernandez-Abanto, Segundo
    Lee, Keunmyoung D.
    Adams, Robert
    CHEMICO-BIOLOGICAL INTERACTIONS, 2013, 203 (01) : 167 - 171
  • [2] In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia™) as a potential nerve agent bioscavenger
    Cerasoli, DM
    Griffiths, EM
    Doctor, BP
    Saxena, A
    Fedorko, JM
    Greig, NH
    Yu, QS
    Huang, Y
    Wilgus, H
    Karatzas, CN
    Koplovitz, I
    Lenz, DE
    CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 157 : 363 - 365
  • [3] Recombinant Human Butyrylcholinesterase As a New-Age Bioscavenger Drug: Development of the Expression System
    Ilyushin, D. G.
    Haertley, O. M.
    Bobik, T. V.
    Shamborant, O. G.
    Surina, E. A.
    Knorre, V. D.
    Masson, P.
    Smirnov, I. V.
    Gabibov, A. G.
    Ponomarenko, N. A.
    ACTA NATURAE, 2013, 5 (01): : 73 - 84
  • [4] Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo
    Ilyushin, Denis G.
    Smirnov, Ivan V.
    Belogurov, Alexey A., Jr.
    Dyachenko, Igor A.
    Zharmukhamedova, Tatiana Iu
    Novozhilova, Tatjana I.
    Bychikhin, Eugene A.
    Serebryakova, Marina V.
    Kharybin, Oleg N.
    Murashev, Arkadii N.
    Anikienko, Konstantin A.
    Nikolaev, Eugene N.
    Ponomarenko, Natalia A.
    Genkin, Dmitry D.
    Blackburn, G. Michael
    Masson, Patrick
    Gabibov, Alexander G.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (04) : 1243 - 1248
  • [5] Partial Biodistribution and Pharmacokinetics of Isoniazid and Rifabutin Following Pulmonary Delivery of Inhalable Microparticles to Rhesus Macaques
    Verma, Rahul Kumar
    Mukker, Jatinder Kaur
    Singh, Ravi Shankar Prasad
    Kumar, Kaushlendra
    Verma, Priya Ranjan Prasad
    Misra, Amit
    MOLECULAR PHARMACEUTICS, 2012, 9 (04) : 1011 - 1016
  • [6] Development of a recombinant butyrylcholinesterase pulmonary bioshield to protect against OP inhalation exposure in macaques
    Rosenberg, Yvonne J.
    Laube, Beth
    Mao, Lingjun
    Jiang, Xiaoming
    Hernandez-Abamto, Segundo
    Adams, Robert
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [7] Pharmacokinetics of intravenous ketorolac following caesarean delivery
    Kulo, A.
    van de Velde, M.
    van Calsteren, K.
    Smits, A.
    de Hoon, J.
    Verbesselt, R.
    Deprest, J.
    Allegaert, K.
    INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA, 2012, 21 (04) : 334 - 338
  • [8] Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
    Yue-Jin Huang
    Paul M Lundy
    Anthoula Lazaris
    Yue Huang
    Hernan Baldassarre
    Bin Wang
    Carl Turcotte
    Mélanie Côté
    Annie Bellemare
    Annie S Bilodeau
    Sandra Brouillard
    Madjid Touati
    Peter Herskovits
    Isabelle Bégin
    Nathalie Neveu
    Eric Brochu
    Janice Pierson
    Duncan K Hockley
    Douglas M Cerasoli
    David E Lenz
    Harvey Wilgus
    Costas N Karatzas
    Solomon Langermann
    BMC Biotechnology, 8
  • [9] Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
    Huang, Yue-Jin
    Lundy, Paul M.
    Lazaris, Anthoula
    Huang, Yue
    Baldassarre, Hernan
    Wang, Bin
    Turcotte, Carl
    Cote, Melanie
    Bellemare, Annie
    Bilodeau, Annie S.
    Brouillard, Sandra
    Touati, Madjid
    Herskovits, Peter
    Begin, Isabelle
    Neveu, Nathalie
    Brochu, Eric
    Pierson, Janice
    Hockley, Duncan K.
    Cerasoli, Douglas M.
    Lenz, David E.
    Wilgus, Harvey
    Karatzas, Costas N.
    Langermann, Solomon
    BMC BIOTECHNOLOGY, 2008, 8 (1)
  • [10] Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model
    Rosenberg, Yvonne J.
    Saxena, Ashima
    Sun, Wei
    Jiang, Xiaoming
    Chilukuri, Nageswararao
    Luo, Chunjuan
    Doctor, Bhupendra P.
    Lee, Keunmyoung D.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2010, 187 (1-3) : 279 - 286